Combination immunotherapy improves outcomes in NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase II COAST clinical trial demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non-small cell lung cancer, according to researchers at Yale Cancer Center, Cancer Center of Kansas, University of Colorado, Abramson Cancer Center, Astrazenaca, and collaborating international organizations.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

FDA issued a Complete Response Letter to Summit Therapeutics Inc. regarding the Biologics License Application for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, who have received prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. Ivonescimab is a novel PD-1 x VEGF bispecific antibody.
FDA granted accelerated approval to Nelkarmi (neladalkib) for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer who have previously received the following therapy in the unresectable locally advanced or metastatic setting: one prior ALK tyrosine kinase inhibitor consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy.
Piktor, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel to patients with advanced endometrioid endometrial cancer and a PI3K/AKT/mTOR pathway mutation who had received at least one prior line of therapy, yielded a 33% confirmed objective response rate in efficacy-evaluable patients, and a disease control rate of 83%, according to clinical data from phase II trial (FTH-PIK-201; NCT06463028; GOG-311). 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login